WST Quote, Financials, Valuation and Earnings

Accuray, Inc. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of -23.08%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat Accuray, Inc.'s return on equity of -33.8%.

West Pharmaceutical Services, Inc. has a consensus price target of $350.77, signalling upside risk potential of 31.54%. On the other hand Accuray, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 249.1%. Given that Accuray, Inc. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Accuray, Inc. is more attractive than West Pharmaceutical Services, Inc..

West Pharmaceutical Services, Inc. has a beta of 1.083, which suggesting that the stock is 8.276% more volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.391, suggesting its more volatile than the S&P 500 by 39.131%.

West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.32%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are larger than Accuray, Inc. quarterly revenues of $93.9M. West Pharmaceutical Services, Inc.'s net income of $140M is higher than Accuray, Inc.'s net income of -$21.7M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 39.50x while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.44x versus 0.27x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 14.91%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat Boston Scientific Corp.'s return on equity of 12.46%.

West Pharmaceutical Services, Inc. has a consensus price target of $350.77, signalling upside risk potential of 31.54%. On the other hand Boston Scientific Corp. has an analysts' consensus of $126.48 which suggests that it could grow by 20.48%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Boston Scientific Corp., analysts believe West Pharmaceutical Services, Inc. is more attractive than Boston Scientific Corp..

West Pharmaceutical Services, Inc. has a beta of 1.083, which suggesting that the stock is 8.276% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.581, suggesting its less volatile than the S&P 500 by 41.925%.

West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.32%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. West Pharmaceutical Services, Inc.'s net income of $140M is lower than Boston Scientific Corp.'s net income of $755M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 39.50x while Boston Scientific Corp.'s PE ratio is 56.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.44x versus 8.10x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 28.31%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.

West Pharmaceutical Services, Inc. has a consensus price target of $350.77, signalling upside risk potential of 31.54%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $592.96 which suggests that it could grow by 4.85%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe West Pharmaceutical Services, Inc. is more attractive than Intuitive Surgical, Inc..

West Pharmaceutical Services, Inc. has a beta of 1.083, which suggesting that the stock is 8.276% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.617, suggesting its more volatile than the S&P 500 by 61.667%.

West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.32%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.5B. West Pharmaceutical Services, Inc.'s net income of $140M is lower than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 39.50x while Intuitive Surgical, Inc.'s PE ratio is 74.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.44x versus 21.39x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Envista Holdings Corp. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of -4.52%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat Envista Holdings Corp.'s return on equity of 0.5%.

West Pharmaceutical Services, Inc. has a consensus price target of $350.77, signalling upside risk potential of 31.54%. On the other hand Envista Holdings Corp. has an analysts' consensus of $22.00 which suggests that it could grow by 10.61%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Envista Holdings Corp., analysts believe West Pharmaceutical Services, Inc. is more attractive than Envista Holdings Corp..

West Pharmaceutical Services, Inc. has a beta of 1.083, which suggesting that the stock is 8.276% more volatile than S&P 500. In comparison Envista Holdings Corp. has a beta of 1.051, suggesting its more volatile than the S&P 500 by 5.074%.

West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.32%. Envista Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. Envista Holdings Corp. pays out -- of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are larger than Envista Holdings Corp. quarterly revenues of $669.9M. West Pharmaceutical Services, Inc.'s net income of $140M is higher than Envista Holdings Corp.'s net income of -$30.3M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 39.50x while Envista Holdings Corp.'s PE ratio is 237.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.44x versus 1.30x for Envista Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.